




United Therapeutics Corporation History

Please see Important Safety Information for our FDA approved products under the Research and Medicine tab.

2024



United Therapeutics Corporation Annual Report

[VIEW 2024 REPORT >](#)

[WATCH THE VIDEO >](#)

First successful transplant of a porcine xenothymokidney

[READ THE PRESS RELEASE >](#)



First successful transplant of a xenokidney from a pig with ten gene edits 500th lung transplant using UT's EVLP service

[READ THE PRESS RELEASE >](#)

2023



United Therapeutics and Miromatrix Medical announce completion of tender offer and merger

[READ THE PRESS RELEASE >](#)

[Skip to main content](#)



United Therapeutics acquires IVIVA Medical Inc.



United Therapeutics Corporation Annual Report

[VIEW 2023 REPORT >](#)

2022

First successful xenotransplantation of porcine heart

[READ THE PRESS RELEASE >](#)



Tyvaso DPI® (treprostinil) inhalation powder approved by the FDA for the treatment of PAH and PH-ILD to improve exercise capacity

[READ THE PRESS RELEASE >](#)

[VISIT TYVASO DPI PAGE >](#)



United Therapeutics Corporation Annual Report

[VIEW 2022 REPORT >](#)

2021

[Skip to main content](#)



INCREASE results published in New England Journal of Medicine

[READ THE PRESS RELEASE >](#)

REMODULIN[®]
(treprostinil) Injection



Commercial launch of the Remunity[®] Pump for Remodulin[®]

[READ THE PRESS RELEASE >](#)

TYVASO[®]
(treprostinil) INHALATION
SOLUTION

FDA approval and launch of Tyvaso[®] for the treatment of PH-ILD

[READ THE PRESS RELEASE >](#)

UT becomes a public benefit corporation

[READ THE PRESS RELEASE >](#)



United Therapeutics Corporation Annual Report

[VIEW 2021 REPORT >](#)

2020

FDA clearance of pharmacy fill Remunity[®] Pump for Remodulin[®]

[READ THE PRESS RELEASE >](#)

[VISIT REMUNITY WEBSITE >](#)



UT issues first Corporate Responsibility Report

[READ THE PRESS RELEASE >](#)

[Skip to main content](#)



INCREASE study of Tyvaso® in PH-ILD meets primary endpoint

[READ THE PRESS RELEASE >](#)



UT launches TETON study in IPF

[READ THE PRESS RELEASE >](#)



United Therapeutics Corporation Annual Report

[VIEW 2020 REPORT >](#)

2019

UT in-licenses Ralinepag an oral, IP receptor agonist being developed for PAH

[READ THE PRESS RELEASE >](#)



Orenitram® label expansion and relaunch

[READ THE PRESS RELEASE >](#)



United Therapeutics Corporation Annual Report

[Skip to main content](#)

2018



FREEDOM-EV study of Orenitram® meets primary endpoint

[READ THE PRESS RELEASE >](#)



UT launches collaboration with MannKind for Tyvaso DPI®

[READ THE PRESS RELEASE >](#)



Health Canada approves Unituxin®

[READ THE PRESS RELEASE >](#)



United Therapeutics Corporation Annual Report

[VIEW 2018 REPORT >](#)

2017



[Skip to main content](#) y, Lung Biotechnology PBC, launches organ bioprinting program in collaboration with 3D Systems



FDA approves TD-300 Nebulizer for Tyvaso®

[READ THE PRESS RELEASE >](#)



United Therapeutics Corporation Annual Report

[VIEW 2017 REPORT >](#)

2016



Launch of Unither 2.0, Major Pipeline Expansion


UT obtains \$1 billion unsecured line of credit



United Therapeutics Corporation Annual Report

[VIEW 2016 REPORT >](#)

2015



Unituxin® approved by FDA to treat high-risk neuroblastoma

[READ THE PRESS RELEASE >](#)

[VISIT UNITUXIN WEBSITE >](#)

UT enters into collaboration with Mayo Clinic to build and operate an ex-vivo lung perfusion center in Jacksonville, Florida

[Skip to main content](#)



United Therapeutics Corporation Annual Report

[VIEW 2015 REPORT >](#)

2014



Japanese regulators approve Remodulin® for PAH under the brand name Treprost™

[READ THE PRESS RELEASE >](#)



First ex-vivo lung perfusion procedure performed by Lung Bioengineering, a subsidiary of UT

[VISIT LUNG BIOENGINEERING WEBSITE >](#)



UT opens Regenerative Medicine Lab in Research Triangle Park, North Carolina, with a focus on manufacturing lungs and lung lobes for transplant

UT and DEKA Research & Development Corp. enter into an agreement to develop a next-generation subcutaneous pump for Remodulin®, which ultimately resulted in the Remunity® Pump for Remodulin®

[READ THE PRESS RELEASE >](#)

[Skip to main content](#)



United Therapeutics Corporation Annual Report

[VIEW 2014 REPORT >](#)

2013



Orenitram® approved by FDA for the treatment of PAH to improve exercise capacity

[READ THE PRESS RELEASE >](#)[VISIT ORENITRAM WEBSITE >](#)

UT annual revenues surpass \$1 billion



United Therapeutics Corporation Annual Report

[VIEW 2013 REPORT >](#)

2011

FREEDOM-M study of Orenitram® meets primary endpoint

[READ THE PRESS RELEASE >](#)

Intravenous Remodulin® approved in most of E.U.

[READ THE PRESS RELEASE >](#)

Adcirca® becomes most prescribed drug for PAH

United Therapeutics acquires Revivacor xenotransplantation program

[Skip to main content](#)



United Therapeutics Corporation Annual Report

[VIEW 2011 REPORT >](#)

Annual Report Soundtrack

01 – “Dear Shareholders” performed by the Alan Scott Band

▶ 0:00 / 4:14

02 – “Live it up” performed by the Alan Scott Band

▶ 0:00 / 4:40

03 – “2011” performed by the Alan Scott Band

▶ 0:00 / 4:25

04 – “Helicopter” performed by the Alan Scott Band

▶ 0:00 / 2:51

2010

United Therapeutics launches collaboration with National Cancer Institute to develop a monoclonal antibody for treatment of high-risk neuroblastoma, which is today known as Unituxin®



United Therapeutics Corporation Annual Report

[VIEW 2010 REPORT >](#)

2009

UT surpasses \$1 billion in assets

[Skip to main content](#)



tadalafil tablets 20mg

Adcirca® approved by FDA for the treatment of PAH to improve exercise capacity

[READ THE PRESS RELEASE >](#)[VISIT ADCIRCA WEBSITE >](#)

Tyvaso® approved by FDA for the treatment of PAH to improve exercise capacity

[READ THE PRESS RELEASE >](#)[VISIT TYVASO WEBSITE >](#)

United Therapeutics Corporation Annual Report

[VIEW 2009 REPORT >](#)

2008

UT in-licenses U.S. commercialization rights to Adcirca® for PAH from Eli Lilly and Company

[READ THE PRESS RELEASE >](#)

United Therapeutics Corporation Annual Report

[VIEW 2008 REPORT >](#)

2007

TRIUMPH-1 study of inhaled treprostinil meets primary endpoint

[READ THE PRESS RELEASE >](#)[Skip to main content](#)



United Therapeutics Corporation Annual Report

[VIEW 2007 REPORT >](#)

2006

FDA approves expansion of Remodulin® label to include transitions from Flolan®

[READ THE PRESS RELEASE >](#)




United Therapeutics Corporation Annual Report

[VIEW 2006 REPORT >](#)

2005

Remodulin® approved by 23 countries in the European Union for the treatment of PAH to improve exercise capacity by subcutaneous infusion

[READ THE PRESS RELEASE >](#)




United Therapeutics Corporation Annual Report

[VIEW 2005 REPORT >](#)

2004

FDA approves expansion of Remodulin® label to include treatment of PAH by intravenous infusion

[Skip to main content](#)




United Therapeutics Corporation Annual Report

[VIEW 2004 REPORT >](#)

2003

UT commences first human clinical trial of an oral formulation of treprostinil




United Therapeutics Corporation Annual Report

[VIEW 2003 REPORT >](#)

2002

Remodulin® approved in the United States, Canada and Israel to treat PAH by subcutaneous infusion

[VISIT REMODULIN WEBSITE >](#)



United Therapeutics Corporation Annual Report

[VIEW 2002 REPORT >](#)

2001

[Skip to main content](#)



United Therapeutics Corporation Annual Report

[VIEW 2001 REPORT >](#)

2000

UT submits new drug application to FDA for **Remodulin®** to treat pulmonary arterial hypertension

1999

United Therapeutics acquires rights to **treprostinil** from Glaxo Wellcome Inc.

United Therapeutics acquires Synquest, Inc., providing in-house capacity and expertise to manufacture treprostinil

1997

Initial public offering (Nasdaq:UTHR), priced at \$12.00 per share

1996



United Therapeutics founded by **Martine Rothblatt** to find a cure for her daughter's life-threatening condition, now known as pulmonary arterial hypertension

Stay Informed

[Skip to main content](#)

Get highlights of the most important news delivered to your email inbox.



© 2025 United Therapeutics Corporation

All rights reserved

US-CORP-377 UTHR

[Cookie Preferences](#)

[Privacy Policy](#) [Consumer Health Privacy](#) [Terms of Use](#) [Transparency Documents](#) [Training](#) [Investor Relations](#)

